[{"orgOrder":0,"company":"N-Zyme Biomedical","sponsor":"LGM Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Fosamprenavir Sodium Alginate","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"N-Zyme Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"N-Zyme Biomedical \/ LGM Pharma","highestDevelopmentStatusID":"4","companyTruncated":"N-Zyme Biomedical \/ LGM Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by N-Zyme Biomedical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The collaboration aims to bring to market a first-in-class, pepsin inhibitor, fosamprenavir that is safe and effective for patients with LPR and/or persistent GERD symptoms.

                          Brand Name : NZYM-001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 18, 2024

                          Lead Product(s) : Fosamprenavir Sodium Alginate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : LGM Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank